Seattle Genetics director resigns
Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy
John McLaughlin resigned as a director of Seattle Genetics Inc. to focus on his responsibilities as president and CEO of PDL BioPharma Inc., effective Dec. 16.
Following McLaughlin's resignation, Daniel Welch was appointed to the board's audit committee.
Welch is an independent director of Seattle Genetics.